JP7282350B2 - タンパク質糖化反応阻害物質の製造方法 - Google Patents
タンパク質糖化反応阻害物質の製造方法 Download PDFInfo
- Publication number
- JP7282350B2 JP7282350B2 JP2017234600A JP2017234600A JP7282350B2 JP 7282350 B2 JP7282350 B2 JP 7282350B2 JP 2017234600 A JP2017234600 A JP 2017234600A JP 2017234600 A JP2017234600 A JP 2017234600A JP 7282350 B2 JP7282350 B2 JP 7282350B2
- Authority
- JP
- Japan
- Prior art keywords
- tea
- water
- solvent
- aqueous solvent
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 33
- 102000004169 proteins and genes Human genes 0.000 title claims description 33
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 230000036252 glycation Effects 0.000 title description 17
- 239000003112 inhibitor Substances 0.000 title description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 21
- 239000003125 aqueous solvent Substances 0.000 claims description 20
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 claims description 15
- 238000000855 fermentation Methods 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 15
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 239000003759 ester based solvent Substances 0.000 claims description 6
- 238000010564 aerobic fermentation Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 3
- 229940072049 amyl acetate Drugs 0.000 claims description 3
- PGMYKACGEOXYJE-UHFFFAOYSA-N anhydrous amyl acetate Natural products CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 claims description 3
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 claims description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 241001122767 Theaceae Species 0.000 claims 3
- 244000269722 Thea sinensis Species 0.000 description 39
- 235000013616 tea Nutrition 0.000 description 38
- 238000000605 extraction Methods 0.000 description 15
- 235000019225 fermented tea Nutrition 0.000 description 12
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 9
- 239000002683 reaction inhibitor Substances 0.000 description 8
- 230000004151 fermentation Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 238000010025 steaming Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 4
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 4
- YKYONYBAUNKHLG-UHFFFAOYSA-N propyl acetate Chemical compound CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 208000002249 Diabetes Complications Diseases 0.000 description 3
- 206010012655 Diabetic complications Diseases 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002038 ethyl acetate fraction Substances 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- LPEKGGXMPWTOCB-UHFFFAOYSA-N 8beta-(2,3-epoxy-2-methylbutyryloxy)-14-acetoxytithifolin Natural products COC(=O)C(C)O LPEKGGXMPWTOCB-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- MRABAEUHTLLEML-UHFFFAOYSA-N Butyl lactate Chemical compound CCCCOC(=O)C(C)O MRABAEUHTLLEML-UHFFFAOYSA-N 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- IPTNXMGXEGQYSY-UHFFFAOYSA-N acetic acid;1-methoxybutan-1-ol Chemical compound CC(O)=O.CCCC(O)OC IPTNXMGXEGQYSY-UHFFFAOYSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 239000001191 butyl (2R)-2-hydroxypropanoate Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 2
- 229940116333 ethyl lactate Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000020347 goishicha tea Nutrition 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 229940011051 isopropyl acetate Drugs 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940057867 methyl lactate Drugs 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- -1 poultices Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000008085 renal dysfunction Effects 0.000 description 2
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 240000006914 Aspalathus linearis Species 0.000 description 1
- 235000012984 Aspalathus linearis Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 240000008441 Camellia sinensis var. assamica Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 240000000691 Houttuynia cordata Species 0.000 description 1
- 235000013719 Houttuynia cordata Nutrition 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 208000003056 Vitamin B6 deficiency Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 239000002034 butanolic fraction Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000020330 rooibos tea Nutrition 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Description
安全なタンパク質糖化反応阻害物質としては、例えば特許文献1にはドクダミ後発酵茶などが、特許文献2には後発酵ルイボス茶などが、特許文献3には碁石茶などが開示されている。
そこで本発明は、タンパク質の糖化反応を有効に阻害することが可能で且つ非常に安全な物質を製造する方法を提供することを目的とする。
以下、本発明を示す。
茶葉を好気的発酵した後に嫌気的発酵して発酵茶を得る工程、
上記発酵茶を水系溶媒により抽出して水系溶媒抽出物を得る工程、および、
上記水系溶媒抽出物をエステル系溶媒により抽出する工程を含むことを特徴とする方法。
[2] 上記発酵茶が碁石茶である上記[1]に記載の方法。
[3] 上記水系溶媒として熱水を用いる上記[1]または[2]に記載の方法。
[4] 上記水系溶媒抽出物の水溶液を上記エステル系溶媒により抽出する上記[1]~[3]のいずれかに記載の方法。
[5] 上記エステル系溶媒として、酢酸エチル、酢酸メチル、酢酸ブチル、酢酸sec-ブチル、酢酸メトキシブチル、酢酸アミル、酢酸ノルマルプロピル、酢酸イソプロピル、乳酸エチル、乳酸メチルおよび乳酸ブチルからなる群から選択される1以上のエステル系溶媒を用いる上記[1]~[4]のいずれかに記載の方法。
[6] タンパク質の糖化反応を阻害する上記物質が飲食品の成分として用いられるものである上記[1]~[5]のいずれかに記載の方法。
[7] タンパク質の糖化反応を阻害する上記物質が外用剤の成分として用いられるものである上記[1]~[5]のいずれかに記載の方法。
1.茶葉の二段発酵工程
本工程では、茶葉を好気的発酵した後に嫌気的発酵して発酵茶を得る。
次に、本工程では、上記二段発酵工程で得られた発酵茶から、水系溶媒を使って水系溶媒抽出物を得る。
本工程では、上記水系溶媒による抽出工程で得られた水系溶媒抽出物から、エステル系溶媒を使って本発明に係るタンパク質糖化反応阻害物質を得る。
上記本発明方法で得られたタンパク質糖化反応阻害物質は、上記二段発酵茶の水系溶媒抽出物に比べてより一層優れたタンパク質糖化反応阻害活性を示す。また、本発明に係るタンパク質糖化反応阻害物質は、飲用にも付される二段発酵茶から更に有効成分を精製したものに相当することから非常に安全なものであり、恒常的で予防的な服用も可能である。
碁石茶粉末(スキンキュア・ラボ社製)4gと精製水1000mLを混合し、超音波を照射しつつ100℃で5分間抽出した。次いで、容器を綿で栓をし、濾過することにより得た濾液を減圧濃縮し、水抽出物を得た。水抽出物4.89gを精製水500mLに溶解し、得られた水溶液を酢酸エチル180mLで3回抽出した。酢酸エチル抽出液を合わせ、無水硫酸ナトリウムで水層と完全に分離した後に減圧濃縮し、酢酸エチル画分0.47gを得た。
Claims (5)
- タンパク質の糖化反応を阻害する物質の製造方法であって、
茶葉を好気的発酵した後に嫌気的発酵して碁石茶を得る工程、
上記碁石茶を水系溶媒により抽出して水系溶媒抽出物を得る工程、および、
上記水系溶媒抽出物をエステル系溶媒により抽出する工程を含み、
上記水系溶媒が、水、または水とメタノールもしくはエタノールとの混合溶媒であり、
上記エステル系溶媒が、酢酸エチル、酢酸ブチルおよび酢酸アミルからなる群から選択される1以上のエステル系溶媒であることを特徴とする方法。 - 上記水系溶媒として熱水を用いる請求項1に記載の方法。
- 上記水系溶媒抽出物の水溶液を上記エステル系溶媒により抽出する請求項1または2に記載の方法。
- タンパク質の糖化反応を阻害する上記物質が飲食品の成分として用いられるものである請求項1~3のいずれかに記載の方法。
- タンパク質の糖化反応を阻害する上記物質が外用剤の成分として用いられるものである請求項1~3のいずれかに記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017234600A JP7282350B2 (ja) | 2017-12-06 | 2017-12-06 | タンパク質糖化反応阻害物質の製造方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017234600A JP7282350B2 (ja) | 2017-12-06 | 2017-12-06 | タンパク質糖化反応阻害物質の製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019099529A JP2019099529A (ja) | 2019-06-24 |
JP7282350B2 true JP7282350B2 (ja) | 2023-05-29 |
Family
ID=66975808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017234600A Active JP7282350B2 (ja) | 2017-12-06 | 2017-12-06 | タンパク質糖化反応阻害物質の製造方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7282350B2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7085174B1 (ja) * | 2021-03-23 | 2022-06-16 | 長峰製茶株式会社 | 嫌気性発酵茶の製造方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004217554A (ja) | 2003-01-14 | 2004-08-05 | Sunnyhealth Co Ltd | カプサイシンアンナム(Capsicumannum)種由来のカプサイシン類配糖体の取得方法及びその組成物 |
JP2012193157A (ja) | 2011-03-03 | 2012-10-11 | Kaneka Corp | 筋肉増量剤 |
WO2013100111A1 (ja) | 2011-12-27 | 2013-07-04 | 油田 正樹 | サーチュイン活性化剤 |
JP2017048152A (ja) | 2015-09-03 | 2017-03-09 | 株式会社ダイセル | 発酵茶抽出物を含む抗糖化剤 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4831133A (en) * | 1987-05-01 | 1989-05-16 | Allelix, Inc. | Extraction of alkaloids of Catharanthus roseus tissue |
-
2017
- 2017-12-06 JP JP2017234600A patent/JP7282350B2/ja active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004217554A (ja) | 2003-01-14 | 2004-08-05 | Sunnyhealth Co Ltd | カプサイシンアンナム(Capsicumannum)種由来のカプサイシン類配糖体の取得方法及びその組成物 |
JP2012193157A (ja) | 2011-03-03 | 2012-10-11 | Kaneka Corp | 筋肉増量剤 |
WO2013100111A1 (ja) | 2011-12-27 | 2013-07-04 | 油田 正樹 | サーチュイン活性化剤 |
JP2017048152A (ja) | 2015-09-03 | 2017-03-09 | 株式会社ダイセル | 発酵茶抽出物を含む抗糖化剤 |
Also Published As
Publication number | Publication date |
---|---|
JP2019099529A (ja) | 2019-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5538611B2 (ja) | メイラード反応阻害剤 | |
JP2014205679A (ja) | 向上した抗酸化活性を有するマスカダイン組成物 | |
WO2009091120A2 (en) | Composition comprising the extracts of lindera obtusiloba for prevention and treatment of cardiovascular diseases | |
KR101757385B1 (ko) | 동백나무 열매 추출물을 포함하는 체내 이상지질혈증, 비만 또는 지방간 예방 및 치료용 약학 조성물 | |
JP2008526737A (ja) | 虚血性疾患及び退行性脳疾患の予防と治療のためのイネ科植物抽出物を含む組成物およびその使用 | |
JP7282350B2 (ja) | タンパク質糖化反応阻害物質の製造方法 | |
JP4979184B2 (ja) | 杜仲葉水抽出成分を含むリパーゼ阻害剤 | |
WO2009091121A2 (en) | Composition comprising the extracts of lysimachia clethroides for prevention and treatment of cardiovascular diseases | |
KR102025572B1 (ko) | 고욤나무 잎 및 포도송이 줄기 추출물의 혼합물을 유효성분으로 함유하는 대사성 질환의 예방, 개선 또는 치료용 조성물 | |
KR100681638B1 (ko) | 고혈당 및 고지혈증 억제 활성을 갖는 감차수국 추출물을 함유한 조성물 | |
JP6122200B1 (ja) | 抗糖化用組成物 | |
KR101182059B1 (ko) | 항산화 활성을 갖는 톳 정유 추출물을 유효성분으로 함유하는 조성물 | |
JP2004525124A (ja) | ヴィティスラブルスカおよびヴィティスヴィニフェラの果皮の浸出物を得るためのプロセス | |
JP2013103936A (ja) | 塩蔵発酵高麗人蔘抽出物を含む組成物 | |
WO2009153500A2 (fr) | Compositions a base de plantes et utilisations | |
JP2009221158A (ja) | 中性脂肪低減剤および体脂肪増加抑制剤 | |
KR20020089216A (ko) | 천연식물 및 한약재 추출물을 함유하는 미백화장료 조성물 | |
JP2003226640A (ja) | アルドースリダクターゼ阻害作用剤 | |
KR20140141845A (ko) | 복분자줄기 추출물을 주성분으로 하는 혈행개선용 조성물 | |
JP6281855B2 (ja) | 後発酵茶由来の血圧上昇抑制作用を有する剤並びにそれを含む飲食品及び医薬 | |
KR102496751B1 (ko) | 비만 예방 기능성 성분을 포함하는 오가피 추출물 및 그 제조 방법 | |
EP2271336A2 (fr) | Procede d'extraction de coumarines | |
KR20180134657A (ko) | 미성숙 감으로부터 폴리페놀을 추출하는 방법 | |
TW200528126A (en) | Whitening agent | |
KR20250082079A (ko) | 미역쇠 추출물을 포함하는 혈당상승억제 활성을 갖는 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20171218 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20171218 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20190308 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190308 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201030 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20201030 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20201030 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211012 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220426 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20221011 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230110 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20230110 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20230124 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230220 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20230221 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230418 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230510 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7282350 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |